Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 7/20 | 0.51 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.40 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6578151 | 0.95 | CTSK (0.56) | CTSKCTSBCTSLCTSSTAOK1 | |
| SCHEMBL6578144 | 0.91 | CTSK (0.55) | CTSKCTSBCTSLCTSSTAOK1 | |
| SCHEMBL6580618 | 0.91 | CTSK (0.54) | CTSKCTSBCTSLCTSSTAOK1 | |
| SCHEMBL6580526 | 0.86 | CTSK (0.51) | CTSKCTSBCTSLCTSSTAOK1 | |
| SCHEMBL6580725 | 0.84 | CTSK (0.47) | CTSKCTSBCTSLCTSS | |
| SCHEMBL6580372 | 0.83 | CTSK (0.75) | CTSKCTSBCTSLCTSS | |
| SCHEMBL6580334 | 0.83 | CTSL (0.50) | CTSKCTSBCTSLCTSS | |
| Lithium Ion SCHEMBL6582305 | 0.82 | CTSK (0.53) | CTSKCTSBCTSLCTSSTAOK1 | |
| SCHEMBL7379929 | 0.82 | CTSK (0.55) | CTSKCTSBCTSLCTSSTAOK1 | |
| SCHEMBL6582647 | 0.81 | CTSK (0.54) | CTSKCTSBCTSLCTSSTAOK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180927-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2004-09-16 | — | — | US | disclosed |
| EP-0936912-B1 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORP (US) | 2004-02-11 | — | — | EP | disclosed |
| US-20020128476-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180927-A1 | Inhibitors of cysteine protease | CTSK, CTSZ, CTSS | CTSK 1/4885CTSB 5/4885CTSL 7/4885 |
| US-20020128476-A1 | Inhibitors of cysteine protease | CTRC, RCE1, CTRL | CTSK 100/4885CTSB 60/4885CTSL 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.